Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.…
Why Is Tencent Music Entertainment Stock Falling 3.1% in Pre-Market Trading?
Tenax Therapeutics (NASDAQ: TENX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 1.250 USD on 20 November 2026, down 81.9% over 52 weeks. Its 52-week range is 1.240 USD to 19.40 USD, and it trades at the bottom of that range.
Its market capitalisation is 56.92M USD.
Tenax Therapeutics reports return on equity of -54.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 113.73M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.